Patent intelligence · US
US 9000089
Polyurea systems, processes for preparing the same and use thereof for postoperative adhesion barriers
Polyurea systems, processes for preparing the same and use thereof for postoperative adhesion barriers
Patent details — US 9000089
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 7, 2015
- Expiration
- Apr 2, 2035
- Applicant
- Medical Adhesive Revolution GmbH
- Claims
- 20
- CPC classes
- A61P, A61P41/00
Quick answer
US 9000089 (Polyurea systems, processes for preparing the same and use thereof for postoperative adhesion barriers) is held by Medical Adhesive Revolution GmbH. Status: granted. Granted Apr 7, 2015. Expires Apr 2, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Medical Adhesive Revolution GmbH
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P41/00
More from Medical Adhesive Revolution GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12409225
Ras inhibitors
granted -
US 12403196
Ras inhibitors
granted -
US 12384750
Ras inhibitors
granted -
US 12365688
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
granted -
US 12280113
Ras inhibitors
granted -
US 12258366
Bicyclic heteroaryl compounds and uses thereof
granted -
US 12252497
Ras inhibitors
granted -
US 12202845
Ras inhibitors
granted
Frequently asked questions
What is US patent 9000089?
US 9000089 (Polyurea systems, processes for preparing the same and use thereof for postoperative adhesion barriers) is held by Medical Adhesive Revolution GmbH. Status: granted. Granted Apr 7, 2015. Expires Apr 2, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9000089?
Medical Adhesive Revolution GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 9000089 expire?
Our index shows an expiration date of Apr 2, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.